Document is current
Any future updates will be listed below
-
Authors
Sanchez Alvarez, Javier
Jaber, Mahmoud
Blanchet Zumofen, Marie-Hélène
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02500407 at ClinicalTrials.govDocuments that mention this clinical trial
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study
https://doi.org/10.1200/jco.23.02329
Automated Lugano Metabolic Response Assessment in <sup>18</sup> F-Fluorodeoxyglucose–Avid Non-Hodgkin Lymphoma With Deep Learning on <sup>18</sup> F-Fluorodeoxyglucose–Positron Emission Tomography
https://doi.org/10.1200/jco.23.01978
Multiple Real-World Data Sources in a Bayesian Framework to Inform Long-Term Survival Estimates of Mosunetuzumab in Patients with Follicular Lymphoma
https://doi.org/10.1007/s40487-023-00245-4
-
Funding
Funding for this research was provided by:
F. Hoffmann-La Roche Ltd
- License Information
-
More Information
Article History
Received: 7 June 2023
Accepted: 5 September 2023
First Online: 18 October 2023
Declarations
:
: Mahmoud Jaber and Marie-Helene Blanchet Zumofen are employees of and own stock in F. Hoffmann-La Roche Ltd. Javier Sanchez Alvarez was an employee of and owned stock in F. Hoffmann-La Roche Ltd during the development of this manuscript and is currently employed by Evidera Ltd.
: The original trials used in this analysis obtained patient consent to participate and were performed in accordance with the Helsinki Declaration of 1964. All ethical approvals and permission to access and use non-public data have been granted for this study. All remaining data are publicly available.
